TLX Stock Analysis: Talanx | XETRA
Insurance - Diversified | XETRA, Germany | Market Cap: 30.781m EUR | 12M Return: 3.3% | DE000TLX1005 | Charts, Fundamentals & Technical Analysis
Avg Turnover: 16.8M
EPS Trend: 92.7%
Rev. Trend: 70.7%
Qual. Beats: 0
Warnings
No concerns identified
Tailwinds
Seasonality 11.6 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
Talanx AG is a Germany-based multi-line insurance and reinsurance company offering a broad range of life and non-life products, including motor, property, casualty, health, aviation, marine, credit and surety, and cyber coverage. It also operates bancassurance, structured and facultative reinsurance, nat cat and asset management activities, and distributes through both standard and customized offerings. The groups portfolio spans multiple insurance lines, which is characteristic of multi-line carriers that diversify earnings across life and property-and-casualty segments.
The company distributes its products globally, with operations across Germany, the United Kingdom, Türkiye, Central and Eastern Europe, the wider European region, the United States, Latin America, Asia, Australia, and Africa. Founded in 1903 and headquartered in Hanover, Talanx is a subsidiary of HDI Haftpflichtverband der Deutschen Industrie V.a.G., a mutual liability association (Versicherungsverein auf Gegenseitigkeit), a legal form in the German insurance market in which policyholders hold membership rights in the parent entity.
- Hannover Re nat cat claims and treaty pricing drive group earnings
- Higher interest rates lift investment income on insurance reserves
- International and specialty insurance growth expands premium base
| Net Income: 2.60b TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.04 > 0.02 and ΔFCF/TA -0.57 > 1.0 |
| NWC/Revenue: 18.97% < 20% (prev 517.6%; Δ -498.7% < -1%) |
| CFO/TA 0.04 > 3% & CFO 8.37b > Net Income 2.60b |
| Net Debt (4.91b) to EBITDA (5.12b): 0.96 < 3 |
| Current Ratio: error (cannot be calculated; needs correct Total Current Assets and Liabilities) |
| Outstanding Shares: last quarter (258.2m) vs 12m ago 0.0% < -2% |
| Gross Margin: 85.47% > 18% (prev 100.0%; Δ -14.53% > 0.5%) |
| Asset Turnover: 37.48% > 50% (prev 13.09%; Δ 24.40% > 0%) |
| Interest Coverage Ratio: 27.08 > 6 (EBIT TTM 4.98b / Interest Expense TTM 184.0m) |
| A: 0.07 (Total Current Assets 13.0b - Total Current Liabilities 0.0) / Total Assets 189b |
| B: 0.07 (Retained Earnings 12.9b / Total Assets 189b) |
| C: 0.03 (EBIT TTM 4.98b / Avg Total Assets 183b) |
| D: 0.09 (Book Value of Equity 14.4b / Total Liabilities 167b) |
| Altman-Z'' = 0.95 = BB |
| DSRI: 0.32 (Receivables 8.67b/9.20b, Revenue 68.7b/23.2b) |
| GMI: 1.17 (GM 100.0% / 85.47%) |
| AQI: 2.97 (AQ_t 0.93 / AQ_t-1 0.31) |
| SGI: 2.96 (Revenue 68.7b / 23.2b) |
| TATA: -0.03 (NI 2.60b - CFO 8.37b) / TA 189b) |
| Beneish M = -0.86 (Cap -4..+1) = D |
As of August 22, 2026, the stock is trading at EUR 120.80 with a total of 124,464 shares traded. Over the past week, the price has changed by +1.94%, over one month by +9.12%, over three months by +11.03% and over the past year by +3.29%.
Current recommended Stop Loss: 117.80 (which is 2.5% or 1.3 ATR below the current price).
Talanx has no consensus analysts rating.
P/E Trailing = 11.8254
P/E Forward = 10.3413
P/S = 0.7238
P/B = 2.1103
P/EG = 3.232
Revenue TTM = 68.7b EUR
EBIT TTM = 4.98b EUR
EBITDA TTM = 5.12b EUR
Long Term Debt = 7.90b EUR (from longTermDebt, last fiscal year)
Short Term Debt = 1.73b EUR (from shortTermDebt, last fiscal year)
Debt = 9.27b EUR (from shortLongTermDebtTotal, last quarter) + Leases 367.0m
Net Debt = 4.91b EUR (calculated: Debt 9.27b - CCE 4.36b)
Enterprise Value = 35.7b EUR (30.8b + Debt 9.27b - CCE 4.36b)
Interest Coverage Ratio = 27.08 (Ebit TTM 4.98b / Interest Expense TTM 184.0m)
EV/FCF = 4.51x (Enterprise Value 35.7b / FCF TTM 7.92b)
FCF Yield = 22.19% (FCF TTM 7.92b / Enterprise Value 35.7b)
FCF Margin = 11.53% (FCF TTM 7.92b / Revenue TTM 68.7b)
Net Margin = 3.79% (Net Income TTM 2.60b / Revenue TTM 68.7b)
Gross Margin = 85.47% ((Revenue TTM 68.7b - Cost of Revenue TTM 9.98b) / Revenue TTM)
Gross Margin QoQ = 34.97% (prev none%)
Tobins Q-Ratio = 0.19 (Enterprise Value 35.7b / Total Assets 189b)
Interest Expense / Debt = 1.99% (Interest Expense 184.0m / Debt 9.27b)
Taxrate = 25.63% (1.28b / 4.98b)
NOPAT = 3.71b (EBIT 4.98b * (1 - 25.63%))
Current Ratio = unknown (Total Current Assets 13.0b / Total Current Liabilities 0.0)
Debt / Equity = 0.64 (Debt 9.27b / totalStockholderEquity, last quarter 14.4b)
Debt / EBITDA = 0.96 (Net Debt 4.91b / EBITDA 5.12b)
Debt / FCF = 0.62 (Net Debt 4.91b / FCF TTM 7.92b)
Total Stockholder Equity = 10.1b (last 4 quarters mean from totalStockholderEquity)
RoA = 1.42% (Net Income 2.60b / Total Assets 189b)
RoE = 25.67% (Net Income TTM 2.60b / Total Stockholder Equity 10.1b)
RoCE = 27.61% (EBIT 4.98b / Capital Employed (Equity 10.1b + L.T.Debt 7.90b))
RoIC = 2.70% (EBIT 4.98b / (Assets 189b - Curr.Liab 0.0 - Cash 4.36b))
WACC = 5.07% (E(30.8b)/V(40.0b) * Re(6.15%) + D(9.27b)/V(40.0b) * Rd(1.99%) * (1-Tc(0.26)))
Discount Rate = 6.15% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 34.82 | Cagr: 0.0%
[DCF] Terminal Value 74.57% ; FCFF base≈8.12b ; Y1≈7.74b ; Y5≈7.39b
[DCF] Fair Price = 431.0 (EV 116b - Net Debt 4.91b = Equity 111b / Shares 258.2m; r=8.35% [WACC [floored]]; 5y FCF grow -6.08% → 2.50% )
EPS Correlation: 92.73 | EPS CAGR: 18.43% | SUE: N/A | # QB: 0
Revenue Correlation: 70.71 | Revenue CAGR: 48.10% | SUE: 0.28 | # QB: 0
EPS current Quarter (2026-09-30): EPS=2.94 | Chg30d=N/A | Revisions=+0% | Analysts=1
EPS current Year (2026-12-31): EPS=11.14 | Chg30d=+2.10% | Revisions=+57% | GrowthEPS=+16.0% | GrowthRev=+1.8%
EPS next Year (2027-12-31): EPS=11.57 | Chg30d=+0.96% | Revisions=+17% | GrowthEPS=+3.9% | GrowthRev=+3.5%
[Analyst] Revisions Ratio: +50% (up=6, down=1)